

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **DISCLOSEABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCT**

### **PURCHASE OF WEALTH MANAGEMENT PRODUCT**

At the 21st meeting held by the second session of the Board on March 27, 2025, a resolution regarding cash management using self-owned funds was considered and approved, pursuant to which the Company may purchase principal-guaranteed bank wealth management products using part of idle self-owned funds of not more than RMB500.0 million.

The Board announces that, on November 3, 2025, the Company entered into the SPDB Wealth Management Product Agreement with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB400.0 million from SPDB Yantai Branch using idle self-owned funds.

### **LISTING RULES IMPLICATIONS**

As the Company entered into another wealth management product agreement with SPDB on October 15, 2025 and still holds the wealth management product under this agreement, the transactions contemplated under this wealth management product agreement and the SPDB Wealth Management Product Agreement are conducted with the same bank and are of similar nature within a 12-month period. For the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreement (calculated on an aggregation basis with the aforesaid another wealth management product agreement) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the SPDB Wealth Management Product Agreement therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## **BACKGROUND**

The Board announces that, on November 3, 2025, the Company entered into the SPDB Wealth Management Product Agreement with SPDB Yantai Branch, pursuant to which the Company agreed to purchase wealth management product of an amount of RMB400.0 million from SPDB Yantai Branch using idle self-owned funds.

## **SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT**

The principal terms of the SPDB Wealth Management Product Agreement are set out as follows:

Name of product	: Liduoduo Corporate Stable Profit 25JG4125 (Monthly Compound Interest Undertaking Payment) RMB Corporate Structured Deposit (利多多公司穩利25JG4125期(月月滾利承接款)人民幣對公結構性存款)
Type of product	: Principal-guaranteed with floating income
Linked target	: EUR-USD exchange rate
Principal amount	: RMB400.0 million
Validity period of product	: 25 days
Effective date of product	: November 3, 2025
Expiry date of product	: November 28, 2025
Expected annualized yield rate	: 0.7% or 1.65% or 1.85%
Right of early termination	: SPDB Yantai Branch has the right to early terminate the agreement.
Investment scope	: The proceeds from the sales of this structured deposit product will be nominal principal, the capital costs of which will be used to enter into transactions with counterparty to make investment in financial derivatives linked to the counterparty's investment income and the EUR-USD spot rate.

The terms of the SPDB Wealth Management Product Agreement were determined upon arm's length negotiations between the parties.

## **PRIOR PURCHASE**

On October 15, 2025, the Company entered into a wealth management product agreement with SPDB Yantai Branch, pursuant to which the Company agreed to purchase a principal-guaranteed with floating income wealth management product in the amount of RMB100.0 million from SPDB Yantai Sub-branch using idle raised proceeds, with a term of 30 days and an expected annualised yield rate of 0.7% or 1.8% or 2%.

## **INFORMATION ON THE PARTIES**

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

SPDB is a bank incorporated in the PRC, the shares of which are listed on the Shanghai Stock Exchange (stock code: 600000). The principal businesses of SPDB are providing corporate and personal banking services, conducting treasury business, and providing asset management and other financial services. SPDB Yantai Branch is a branch of SPDB.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, SPDB Yantai Branch, SPDB and their ultimate substantial beneficial owners as publicly disclosed by SPDB are third parties independent from the Company and its connected persons.

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE SPDB WEALTH MANAGEMENT PRODUCT AGREEMENT**

The reasonable and efficient use of idle self-owned funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The impact of risk factors on the expected return of the SPDB Wealth Management Product Agreement is low, but the Company could get a higher rate of return as compared with fixed-term deposits in commercial banks in the PRC.

The Directors consider that the terms of the SPDB Wealth Management Product Agreement and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As the Company entered into another wealth management product agreement with SPDB on October 15, 2025 and still holds the wealth management product under this agreement, the transactions contemplated under this wealth management product agreement and the SPDB Wealth Management Product Agreement are conducted with the same bank and are of similar nature within a 12-month period. For the purpose of calculating the relevant percentage ratios under Rule 14.22 of the Listing Rules, these transactions shall be aggregated in each case as if they were one transaction with the said bank.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the SPDB Wealth Management Product Agreement (calculated on an aggregation basis with the aforesaid another wealth management product agreement) exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management product under the SPDB Wealth Management Product Agreement therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

## DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors of the Company
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“EUR”	Euro, the lawful currency of the European Union
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“SPDB”	Shanghai Pudong Development Bank Co., Ltd., a bank incorporated in the PRC
“SPDB Wealth Management Product Agreement”	the wealth management product agreement entered into between the Company and SPDB Yantai Branch dated November 3, 2025 in relation to the purchase of wealth management product in the amount of RMB400.0 million
“SPDB Yantai Branch”	Yantai Branch of Shanghai Pudong Development Bank Co., Ltd.

“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“USD”	United States dollar, the lawful currency of the United States of America
“%”	percent

By order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive director*

Yantai, the PRC  
November 3, 2025

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.*

\* *For identification purpose only*